Finance

Lists
ATRA:NASDAQ
Atara Biotherapeutics Inc
$9.17
-0.11%
(-0.010) 1D
Oct 19, 1:33:16 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATRA...
Open
$9.03
High
$9.35
Low
$9.03
Mkt. cap
92.05M
Avg. vol.
45.53K
Volume
4.40K
52-wk high
$19.14
52-wk low
$3.92
EPS
-$1.18
Beta
0.21
Shares outstanding
10.04M
No. of employees
10
Open
$9.03
High
$9.35
Low
$9.03
Mkt. cap
92.05M
Avg. vol.
45.53K
Volume
4.40K
52-wk high
$19.14
52-wk low
$3.92
EPS
-$1.18
Beta
0.21
Shares outstanding
10.04M
No. of employees
10
News stories
From web sources and news partners
TradingView
TradingView
·
31 minutes ago
Midday Pulse: S&P 500 top intraday gainers
bloomingbit
bloomingbit
·
1 hour ago
U.S. Stocks Turn Higher; Nasdaq Up 1.36%
Investor's Business Daily
Investor's Business Daily
·
33 minutes ago
Magnificent Seven Are Losing Their Earnings Luster
FXStreet
FXStreet
·
1 hour ago
The S&P 500 is on a dangerous path
About Atara Biotherapeutics Inc
CEO-
Employees10
Founded2012
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteatarabio.com
Analyst ratings
Based on 2 analysts giving stock ratings to ATRA in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for ATRA in the last 3 months.
Highest
Current $9.17
$18.00 (+96.29%)
Average
$15.50 (+69.03%)
Lowest
$13.00 (+41.77%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
$13.00
+41.8%
10/14/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$18.00
+96.3%
08/31/2026
Ilya Zubkov
Freedom Capital Markets
Hold
Upgraded
$10.00
+9.1%
05/18/2026
Last report
Aug 12, 2026
Fiscal period
Q2 2026
-$0.32 / -$0.25
-28.00%miss
Revenue / Est. (USD)
630.00K / 366.67K
+71.82%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.45M
1.60M
516.00K
630.00K
Cost of goods sold
3.02M
783.00K
288.00K
1.54M
Cost of revenue
3.02M
783.00K
288.00K
1.54M
Research and development expenses
-
2.86M
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.98M
3.47M
3.60M
3.05M
Operating expense
3.98M
6.33M
3.60M
3.05M
Total operating expenses
7.00M
7.11M
3.88M
4.58M
Operating income
-3.55M
-5.52M
-3.37M
-3.95M
Other non operating income
4.00K
-49.00K
-
-
EBT including unusual items
-4.28M
-3.41M
-4.14M
-4.83M
EBT excluding unusual items
-4.25M
-6.36M
-4.14M
-4.07M
Income tax expense
28.00K
-
-
1.00K
Effective tax rate
-0.65%
-
-
-0.02%
Other operating expenses
-
-
-
-
Net income
-4.30M
-3.41M
-4.14M
-4.83M
Net profit margin
-124.62%
-213.54%
-803.29%
-767.30%
Earnings per share
-0.32
-0.35
-0.29
-0.32
Interest and investment income
204.00K
100.00K
54.00K
78.00K
Interest expense
-909.00K
-894.00K
-830.00K
-191.00K
Net interest expenses
-705.00K
-794.00K
-776.00K
-113.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-3.19M
-4.47M
-3.34M
-3.94M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps